کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2136826 | 1087813 | 2013 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies](/preview/png/2136826.png)
چکیده انگلیسی
A phase I dose-escalation study of MSC1992371A, an oral aurora kinase inhibitor, was carried out in patients with hematologic malignancies. Patients received escalating doses either on days 1–3 and 8–10 (n = 36) or on days 1–6 (n = 39) of a 21-day cycle. The maximum tolerated doses were 37 and 28 mg/m2/day, respectively. Dose-limiting toxicities included severe neutropenia with infection and sepsis, mucositis/stomatitis, and diarrhea. Complete responses occurred in 3 patients. Four disease-specific expansion cohorts then received the dose and schedule dictated by the escalation phase but the study was prematurely discontinued due to hematologic and gastrointestinal toxicity at clinically effective doses.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 37, Issue 9, September 2013, Pages 1100–1106
Journal: Leukemia Research - Volume 37, Issue 9, September 2013, Pages 1100–1106
نویسندگان
Carlos Graux, Anne Sonet, Johan Maertens, Justus Duyster, Jochen Greiner, Yves Chalandon, Giovanni Martinelli, Dagmar Hess, Dominik Heim, Francis J. Giles, Kevin R. Kelly, Athos Gianella-Borradori, Blandine Longerey, Ekaterine Asatiani, Narmyn Rejeb,